Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning.
Level 5 - mechanism / opinion, no new human data
Narrative review of landmark clinical trials without systematic review methodology
PubMed 40731911 · doi:10.3390/medicina61071280
What was done
The authors conducted a literature review assessing endocrine treatment approaches for premenopausal and postmenopausal women with early-stage hormone receptor-positive breast cancer, focusing on landmark clinical trials including TEXT, SOFT, ATLAS, and aTTom.
What was found
The abstract provides qualitative consensus recommendations without specific quantitative metrics or hazard ratios. For premenopausal women with low recurrence risk, 5-year tamoxifen monotherapy is standard; intermediate-to-high risk patients benefit from ovarian function suppression combined with an aromatase inhibitor or tamoxifen, potentially with extended duration. For postmenopausal women with low risk, 5 years of an aromatase inhibitor is standard, whereas intermediate-to-high risk cases may require combination approaches and extended treatment durations.
Why it matters
It summarizes treatment algorithms that tune the choice, intensity, and duration of adjuvant endocrine regimens according to a patient's menopausal status and recurrence risk.
Limits
The paper is a narrative overview rather than a systematic review or meta-analysis, lacking predefined search protocols or formal risk-of-bias assessments. The abstract reports no numerical outcome statistics, effect sizes, survival percentages, or toxicity rates.
Cited by
- contradicts Anastrozole is a chemotherapy medication that is toxic to the kidneys.